MannKind Bilan de santé
Santé financière contrôle des critères 0/6
MannKind possède un total de capitaux propres de $-51.0M et une dette totale de $354.6M, ce qui porte son ratio d'endettement à -695.1%. Son actif total et son passif total sont $792.2M et de $843.2M. L'EBIT de MannKind est $46.6M ce qui fait que son ratio de couverture des intérêts 1.6. Elle dispose de liquidités et de placements à court terme de $171.3M.
Informations clés
-695.07%
Ratio d'endettement
US$354.64m
Dette
| Ratio de couverture des intérêts | 1.6x |
| Argent liquide | US$171.35m |
| Fonds propres | -US$51.02m |
| Total du passif | US$843.20m |
| Total des actifs | US$792.18m |
Mises à jour récentes de la santé financière
Recent updates
MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.
MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk
Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential
Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
Feb 06MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects
Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment
Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk
Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion
Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating
MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump
Sep 03
Pipeline Advancements And International Expansion Will Shape Future Markets
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
May 11MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
Mar 01MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Dec 17MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Analyse de la situation financière
Passif à court terme: MNKD a des fonds propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à court terme.
Passif à long terme: MNKD a des capitaux propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à long terme.
Historique et analyse du ratio d'endettement
Niveau d'endettement: MNKD a des fonds propres négatifs, ce qui est une situation plus grave qu'un niveau d'endettement élevé.
Réduire la dette: MNKD a des capitaux propres négatifs, nous n'avons donc pas besoin de vérifier si sa dette a diminué au fil du temps.
Couverture de la dette: La dette de MNKD n'est pas bien couverte par le flux de trésorerie opérationnel ( 5.1% ).
Couverture des intérêts: Les paiements d'intérêts de MNKD sur sa dette ne sont pas bien couverts par l'EBIT ( 1.6 x couverture).
Bilan
Découvrir des entreprises saines
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/04/30 10:44 |
| Cours de l'action en fin de journée | 2026/04/30 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
MannKind Corporation est couverte par 29 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |